Alfred Gilman’s approach to distributing public funds wasn’t particularly difficult to understand: he wanted to pay for the best science available. Period.
The pot of money entrusted to Gilman was vast. In 2007, Texas voters approved the largest investment in cancer research outside the federal government: $3 billion, to be spent over 10 years. By way of comparison, NCI grants going to Texas researchers and institutions added up to $240 million a year. CPRIT more than doubled that money. Only Texans were eligible to apply.
Gilman accepted the CPRIT job at age 68, because he thought that it would be a significant contribution to a major research effort, and a nice way to finish out a long career.
| ||Sixty-Nine Cancer Centers Urge HPV VaccinationIn an unprecedented move, 69 NCI-designated cancer centers have come together to advocate for HPV vaccination as a preventive measure against many HPV-related cancers.|
“HPV vaccination is our best defense in stopping HPV infection in our youth and preventing HPV-related cancers in our communities,” the centers said in a consensus statement published Jan. 27. “The HPV vaccine is cancer prevention.”
|PCORI Passes $1.2 Billion in Total Research Funding|
The Patient-Centered Outcomes Research Institute approved $70 million for nine new patient-centered research projects focused on conditions including ductal carcinoma in situ, diabetes, chronic lung disease and migraines.
With these latest awards, PCORI has now approved or awarded more than $1.2 billion in research funding.
- Minesh Mehta named deputy director at Miami Cancer Institute
- Carmen Solórzano named chief of Division of Surgical Oncology at Vanderbilt
- Judy Keen named ASTRO director of scientific affairs
- Tara Yates joins Wistar Institute as director of communications
- Ovarian Cancer National Alliance and Ovarian Cancer Research Fund merge
- UC San Diego Health selects e+CancerCare to operate Chula Vista radiation center
- Harvard Business School launches Precision Trials Challenge
|Drugs and Targets|
- FDA expands Opdivo-Yervoy Label with accelerated approval in melanoma
- Halaven approved for unresectable or metastatic liposarcoma
- Zepatier approved for treatment of chronic hepatitis C